A lower medicine price can lose without being dismissed; an unresolved gate cannot win at any price. This is a separate hypothetical scoring exercise, not an assessment of actual suppliers.
| Criterion | Weight | Candidate A: final score | A points | Candidate B: final score | B points |
|---|---|---|---|---|---|
| Fulfilment and capacity | 20 | 4 | 16.0 | 4 | 16.0 |
| Continuity | 15 | 3 | 9.0 | 4 | 12.0 |
| Total cost and affordability | 20 | 5 | 20.0 | 4 | 16.0 |
| State/cohort readiness | 10 | 4 | 8.0 | 4 | 8.0 |
| Workflow and reporting | 12 | 3 | 7.2 | 4 | 9.6 |
| Patient service | 8 | 4 | 6.4 | 4 | 6.4 |
| Contract and exposure | 10 | 3 | 6.0 | 4 | 8.0 |
| Implementation | 5 | 3 | 3.0 | 4 | 4.0 |
| Total | 100 | 75.6 | 80.0 |
Assume both candidates pass the gates and the ratings satisfy their evidence ceilings. Candidate A merits negotiation or a bounded pilot; Candidate B reaches final award review. A third, cheaper candidate with unresolved route eligibility remains HOLD—unranked.
Because the gap is only 4.4 points, test sensitivity. Reducing Candidate B’s fulfilment rating from 4 to 3 removes four points. The committee should therefore challenge the evidence supporting that rating rather than treat the displayed decimal as precision about future performance.
Explore the table row by row
A working view of the research
Fulfilment and capacity
- Weight
- 20
- Candidate A: final score
- 4
- A points
- 16.0
- Candidate B: final score
- 4
- B points
- 16.0
Sources cited on this page
See the section’s source register for the research context.
Section sources →